June 25, 2024

Acne Medication Market Size to Attain USD 19.17 Bn by 2033

The global acne medication market size accounted for US$ 11.57 billion in 2023 and is projected to reach around USD 19.17 billion by 2033, growing at a CAGR of 19.17 billion by 2033.

Acne Medication Market Size 2024 to 2033

Key Points

  • North America dominated the acne medication market with the largest share of 45% in 2023.
  • Asia Pacific is expected to witness significant growth in the market during the forecast period.
  • By product, the antibiotics segment dominated the market in 2023.
  • By product, the retinoid segment is expected to grow at a notable rate in the market during the forecast period.
  • By routes of administration, the topical segment held the largest share of the market in 2023.
  • By route of administration, the oral segment is expected to grow at the fastest rate in the market during the anticipated period.
  • By age group, the 18-44 segment dominated the market with significant revenue in 2023.
  • By distribution channel, the retail and online segment is expected to witness a significant rate of growth during the forecast period.

Report Summary

The global acne medication market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the acne medication market across the globe.

A comprehensive estimate on the acne medication market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of acne medication during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3924

Acne Medication Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 5.18%
Global Market Size in 2023 USD 11.57 Billion
Global Market Size by 2033 USD 19.17 Billion
U.S. Market Size in 2023 USD 3.64 Billion
U.S. Market Size by 2033 USD 6.04 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Routes of Administration, By Age-Group, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized acne medication market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  Dental Implants and Abutment Systems Market Size Report by 2033

Market Players

The report includes the profiles of key acne medication market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Acne Medication Market Players

  • Galderma S.A.
  • Bausch Health Companies Inc.
  • Mayne Pharma Group Limited
  • Teva Pharmaceutical Industries Ltd
  • Almirall Sa
  • Glaxosmithkline Plc (Gsk)
  • Pfizer Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Limited
  • Johnson & Johnson

Segments Covered in the Report

By Product

  • Antibiotics
  • Retinoids
  • Isotretinoin

By Routes of Administration

  • Topical
  • Oral

By Age-group

  • 18-44 years
  • 10-17 years
  • 45-65 years
  • 65 years and above

By Distribution Channel

  • Retail and Online
  • Hospital

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Acne Medication Market 

5.1. COVID-19 Landscape: Acne Medication Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Acne Medication Market, By Product

8.1. Acne Medication Market Revenue and Volume Forecast, by Product, 2024-2033

8.1.1. Antibiotics

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Retinoids

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Isotretinoin

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Acne Medication Market, By Routes of Administration

9.1. Acne Medication Market Revenue and Volume Forecast, by Routes of Administration, 2024-2033

9.1.1. Topical

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Oral

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Acne Medication Market, By Age-group 

10.1. Acne Medication Market Revenue and Volume Forecast, by Age-group, 2024-2033

10.1.1. 18-44 years

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. 10-17 years

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. 45-65 years

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. 65 years and above

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Acne Medication Market, By Distribution Channel 

11.1. Acne Medication Market Revenue and Volume Forecast, by Distribution Channel, 2024-2033

11.1.1. Retail and Online

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Hospital

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Acne Medication Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Routes of Administration (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Age-group (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Galderma S.A.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bausch Health Companies Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Mayne Pharma Group Limited

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Teva Pharmaceutical Industries Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Almirall Sa

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Glaxosmithkline Plc (Gsk)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Mylan N.V.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sun Pharmaceutical Industries Limited

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com


Prathamesh

Leave a Reply

Your email address will not be published. Required fields are marked *